Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
Corcept Therapeutics (NASDAQ: CORT) announced Atabak Mokari as the new Chief Financial Officer, succeeding Charles Robb, who has transitioned to Chief Business Officer. This appointment comes as the company prepares for significant operational challenges in 2021. Mokari brings nearly 20 years of healthcare finance experience, previously serving as CFO at Bellicum Pharmaceuticals and IRIDEX. Corcept focuses on developing drugs to treat disorders by modulating cortisol effects, with Korlym® being a FDA-approved treatment for Cushing’s syndrome.
- Appointment of Atabak Mokari as CFO adds experienced leadership.
- Transition allows Charles Robb to focus on key operational tasks.
- None.
MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Atabak Mokari has joined the company as Chief Financial Officer. Charles Robb, who has been Corcept’s CFO since September 2011, has assumed the role of Chief Business Officer.
“Atabak’s talent and broad experience make him a welcome addition to our executive team,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Further, his arrival will allow Charlie to focus on the significant administrative and operational tasks we will face in 2021 and beyond.”
Atabak Mokari has nearly 20 years leadership experience in life sciences and healthcare finance. From 2018 to 2020, he was Chief Financial Officer and Vice President of Corporate Development at Bellicum Pharmaceuticals, Inc. He served in the same capacity from 2016 to 2018 at medical device manufacturer IRIDEX. Mr. Mokari was a director at Wells Fargo Securities LLC’s healthcare investment banking group from 2013 to 2016, at UBS’s healthcare investment banking group from 2009 to 2013 and at Credit Suisse’s healthcare investment banking group from 2005 to 2009. Prior to that, he was a member of the business development team at Forest Laboratories, a pharmaceutical company, and an analyst at the private equity firm Olympus Partners and the investment banking firm Bowles Hollowell Conner & Co. Mr. Mokari earned an MBA from The Tuck School of Business at Dartmouth and a B.S. in Chemistry and Biology from Duke University.
About Corcept Therapeutics
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
CONTACT:
Christopher S. James, MD
Director, Investor Relations
Corcept Therapeutics
650-684-8725
cjames@corcept.com
www.corcept.com
FAQ
Who is the new CFO of Corcept Therapeutics?
What role did Charles Robb take after Atabak Mokari's appointment?
What significant experience does Atabak Mokari bring to Corcept?
Which drug did Corcept Therapeutics develop for Cushing's syndrome?
What is the primary focus of Corcept Therapeutics?
